| dbo:abstract |
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. It is a combination of bempedoic acid and ezetimibe. The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation. Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor and ezetimibe is a cholesterol absorption inhibitor. Bempedoic acid works by blocking an enzyme in the liver called adenosine triphosphate citrate lyase, which is involved in making cholesterol. Ezetimibe works by binding to a gut protein called 'Niemann-Pick C1 Like 1', preventing cholesterol from being absorbed into the blood from the gut. The combination was approved for medical use in the United States in February 2020, and in the European Union in March 2020. (en) |
| dbo:alternativeName |
Nexlizet, Nustendi (en) |
| dbo:kegg |
D11794 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/bempedoic%20acid https://druginfo.nlm.nih.gov/drugportal/name/ezetimibe |
| dbo:wikiPageID |
63219765 (xsd:integer) |
| dbo:wikiPageLength |
8820 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1074065277 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Bempedoic_acid dbr:Dyslipidemia dbr:Indication_(medicine) dbr:Oral_administration dbr:Constipation dbr:Cholesterol_absorption_inhibitor dbr:European_Medicines_Agency dbr:Ezetimibe dbc:Hypolipidemic_agents dbr:ATP_citrate_lyase dbr:Hypercholesterolemia dbr:Hyperuricemia dbc:Combination_drugs dbr:Fixed-dose_combination dbr:High_cholesterol |
| dbp:atcPrefix |
10.0 (dbd:nicaraguanCórdoba) |
| dbp:atcSuffix |
BA10 (en) |
| dbp:class |
dbr:Cholesterol_absorption_inhibitor Adenosine triphosphate-citrate lyase inhibitor (en) |
| dbp:component |
Bempedoic acid (en) Ezetimibe (en) |
| dbp:dailymedid |
Bempedoic_acid_and_ezetimibe (en) |
| dbp:kegg |
D11794 (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:licenceEu |
yes (en) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:tradename |
Nexlizet, Nustendi (en) |
| dbp:type |
combo (en) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Drugs.com dbt:ClinicalTrialsGov dbt:Lipid_modifying_agents |
| dct:subject |
dbc:Hypolipidemic_agents dbc:Combination_drugs |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:CombinationDrug dbo:Drug |
| rdfs:comment |
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. It is a combination of bempedoic acid and ezetimibe. The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation. The combination was approved for medical use in the United States in February 2020, and in the European Union in March 2020. (en) |
| rdfs:label |
Bempedoic acid/ezetimibe (en) |
| owl:sameAs |
wikidata:Bempedoic acid/ezetimibe https://global.dbpedia.org/id/BxWQZ |
| prov:wasDerivedFrom |
wikipedia-en:Bempedoic_acid/ezetimibe?oldid=1074065277&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Bempedoic_acid/ezetimibe |
| is dbo:wikiPageRedirects of |
dbr:Ezetimibe/bempedoic_acid dbr:Nustendi dbr:Nexlizet |
| is dbo:wikiPageWikiLink of |
dbr:Ezetimibe/bempedoic_acid dbr:Bempedoic_acid dbr:Nustendi dbr:ATC_code_C10 dbr:Nexlizet |
| is foaf:primaryTopic of |
wikipedia-en:Bempedoic_acid/ezetimibe |